Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original ...

Effective provider segmentation can make or break a new drug launch, and can also improve the lifecycle of existing portfolio ...

We live in a time of hope for millions around the world, as technological advancements and research breakthroughs hold the ...

Biopharmaceutical companies must address the frictions and challenges that have quietly infiltrated the drug development ...

In this podcast episode centered around Scaling Patient Safety through Innovation, Michael Braun-Boghos and Cheryl James share their expertise and perspectives on leveraging innovative approaches to ...

Life Science Leader is an essential business publication for life science executives who work at everything from emerging biotechs to large pharmaceutical companies. Our content is designed to inform ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

While securing timely and affordable access to care and treatment is a top priority in healthcare, the increasing number of strict controls put in place by payers to control spending on costly ...